A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML
收藏DataCite Commons2026-03-31 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012951/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study was to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who underwent hematopoietic stem cell transplant (HCT) and were randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period.
提供机构：
Vivli
创建时间：
2026-03-31
